JAAD International (Dec 2021)
Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and managementCapsule Summary
- Michela Starace, PhD,
- Matilde Iorizzo, PhD,
- Andrea Sechi, MD,
- Aurora Maria Alessandrini, MD,
- Miriam Carpanese, MD,
- Francesca Bruni, MD,
- Giulio Vara, MD,
- Zoe Apalla, MD,
- Daniel Asz-Sigall, MD,
- Stefania Barruscotti, MD,
- Francisco Camacho, PhD,
- Isabella Doche, PhD,
- Bruna Duque Estrada, MD,
- Rachita Dhurat, MD,
- Maria Fernanda Gavazzoni, MD,
- Ramon Grimalt, PhD,
- Matthew Harries, MD,
- Dimitrios Ioannidis, MD,
- Amy McMichael, MD,
- Daniel Fernandes Melo, PhD,
- Rui Oliveira, MD,
- Yuliya Ovcharenko, MD,
- Rodrigo Pirmez, PhD,
- Yuval Ramot, PhD,
- Lidia Rudnicka, PhD,
- Jerry Shapiro, PhD,
- Tatiana Silyuk, MD,
- Rodney Sinclair, PhD,
- Antonella Tosti, PhD,
- Sergio Vano-Galvan, PhD,
- Bianca Maria Piraccini, PhD
Affiliations
- Michela Starace, PhD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Matilde Iorizzo, PhD
- Private Dermatology Practice, Lugano/Bellinzona, Switzerland
- Andrea Sechi, MD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy; Correspondence to: Andrea Sechi, MD, PhD, Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
- Aurora Maria Alessandrini, MD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Miriam Carpanese, MD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Francesca Bruni, MD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Giulio Vara, MD
- Radiology Unit, Policlinico Sant'Orsola, University of Bologna, Bologna, Italy
- Zoe Apalla, MD
- Second Department of Dermatology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Daniel Asz-Sigall, MD
- Private Dermatology Practice, Mexico City, Mexico
- Stefania Barruscotti, MD
- Department of Clinical-Surgical, Diagnostic and Pediatric Science, Institute of Dermatology, IRCCS Fondazione Policlinico San Matteo, University of Pavia, Pavia, Italy
- Francisco Camacho, PhD
- University of Seville, Medical-Surgical Dermatology Department, University Hospital, Seville, Spain
- Isabella Doche, PhD
- Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
- Bruna Duque Estrada, MD
- Centro de Estudos dos Cabelos, Instituto de Dermatologia Prof. Rubem D Azulay, Rio de Janeiro, Brazil
- Rachita Dhurat, MD
- Department of Dermatology, LTM Medical College & Hospital Sion, Mumbai, India
- Maria Fernanda Gavazzoni, MD
- Fluminense Federal University, Antônio Pedro Federal Hospital, Niterói Rio de Janeiro, Brazil
- Ramon Grimalt, PhD
- Facultat de Medicina i Ciencies de la Salut, UIC-Barcelona, Universitat Internacional de Catalunya, Sant Cugat del `Valles, Barcelona, Spain
- Matthew Harries, MD
- Department of Dermatology, Salford Royal NHS Foundation Trust, Manchester, United Kingdom
- Dimitrios Ioannidis, MD
- Department of Dermatology-Venereology, Aristotle University Medical School, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece
- Amy McMichael, MD
- Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
- Daniel Fernandes Melo, PhD
- Department of Dermatology, University of State of Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
- Rui Oliveira, MD
- Trichology Unit, Dermatology Center CUF Descobertas Hospital, Lisbon, Portugal
- Yuliya Ovcharenko, MD
- Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkiv National University Medical School, Kharkiv, Ukraine
- Rodrigo Pirmez, PhD
- Centro de Estudos dos Cabelos, Instituto de Dermatologia Prof. Rubem D Azulay, Rio de Janeiro, Brazil
- Yuval Ramot, PhD
- Department of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- Lidia Rudnicka, PhD
- Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
- Jerry Shapiro, PhD
- The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York City, New York
- Tatiana Silyuk, MD
- Hair Treatment and Transplantation Center, Private Practice, Saint Petersburg, Russia
- Rodney Sinclair, PhD
- Sinclair Dermatology, Melbourne, Australia
- Antonella Tosti, PhD
- Fredric Brandt Endowed Professor of Dermatology, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida
- Sergio Vano-Galvan, PhD
- Dermatology Department, Ramon y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain
- Bianca Maria Piraccini, PhD
- Dermatology-IRCCS Policlinico Sant'Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Journal volume & issue
-
Vol. 5
pp. 11 – 18
Abstract
Background: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. Objective: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. Methods: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. Limitations: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (12 weeks) telogen effluvium.
